ukmla MCQ (SBA): HFrEF therapy optimisation

Instant feedback + full explanation. One question, done properly.

MediumCardiologyHFrEF therapy optimisationukmlamrcp part 1panemrcgp akt

A 66-year-old man with heart failure with reduced EF (HFrEF, EF 30%) on optimal ACEi and beta-blocker remains symptomatic (NYHA II). Next disease-modifying therapy?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.

ukmla MCQ: HFrEF therapy optimisation — Answer & Explanation | iatroX